AmbioPharm (revision 8)

AmbioPharm, Inc. (trading as AMB; ambiopharm.net) is a peptide active-ingredient manufacturer and contract development organisation trading as AmbioPharm from Beijing, China, incorporated in 2003 and supplying research peptides and raw materials with batch documentation.^[1][2]

The organisation is one of twenty-eight covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.^[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.^[4]

Incorporated in Beijing in 2003, the organisation sits with the earlier incorporation dates among the entities covered on this wiki and predates the current research-peptide market by roughly a decade.^[1] The organisation's own material describes a business built on peptide active pharmaceutical ingredient supply and contract development rather than on catalogue distribution alone.^[2]

The organisation describes itself as operating as a contract development and manufacturing organisation alongside its own listings. That is a self-published characterisation and is recorded here as one: nothing available to this wiki establishes the manufacturing arrangements behind it, and a registered business scope is a licensing fact rather than a capability finding.^[2][1]

The documentary base is the registry record, the organisation's own material and purchaser-submitted test reports. No independent coverage has been identified, which is a characteristic of the sector rather than of this entity.

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Purchaser reports describe vialled lyophilised material arriving with a batch-specific certificate naming a lot, and across the submitted set the lot string on the certificate has corresponded to the vial label.^[5] That correspondence is a minimum requirement rather than an achievement.

Two determinations distinguish the submitted set from most entities covered here. Water content by Karl Fischer titration appears on the certificates described, and the counter-ion is reported as a figure with its unit rather than named or omitted.^[5][6] Together with peptide content on a separate line from chromatographic purity, those are what let a purity percentage be read as a statement about mass. Their routine presence is the most useful documentary observation available about this organisation. Reports also describe the release as signed and dated by a named individual rather than initialled.^[5]